Who
Dana Aftab
EVP, Research and Development
Company insider
Files Form 4 as: EVP, Research and Development, Exelixis.
In numbers
- Trades disclosed
- 61
- Buys
- 0
- Sells
- 13
- Bought
- $0
- Sold
- $22.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 5 Jan 2023
- Last trade
- 26 May 2026
- Last filed
- 28 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 May 2026filed 28 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $2.2M43,451 at $50.35 | filing |
| 26 May 2026filed 28 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $2.2M43,451 at $50.35 | filing |
| 15 May 2026filed 19 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.6M30,578 at $51.10 | filing |
| 15 May 2026filed 19 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.6M30,578 at $51.10 | filing |
| 26 Feb 2026filed 2 Mar 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —52,018 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —52,018 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $2.1M47,918 at $44.50 | filing |
| 24 Feb 2026filed 26 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $2.1M47,918 at $44.50 | filing |
| 19 Feb 2026filed 23 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1.3M29,873 at $44.35 | filing |
| 19 Feb 2026filed 23 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1.3M29,873 at $44.35 | filing |
| 15 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.2M26,485 at $43.92 | filing |
| 15 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $559K12,720 at $43.92 | filing |
| 15 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.2M26,485 at $43.92 | filing |
| 15 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $559K12,720 at $43.92 | filing |
| 15 Jan 2026filed 16 Jan 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —119,578 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.2M27,254 at $45.23 | filing |
| 15 Jan 2026filed 16 Jan 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —119,578 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.2M27,254 at $45.23 | filing |
| 21 Nov 2025filed 24 Nov 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code G | —24,000 at $0.00 | filing |
| 11 Nov 2025filed 13 Nov 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $2.1M48,383 at $42.50 | filing |
News
Citizens Jmp Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) StockEXEL · tickerreport.com · 21 Oct 2026Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026
0 headlines in the last 90 days name Dana Aftab; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.